{"id":796,"date":"2018-03-27T14:53:00","date_gmt":"2018-03-27T06:53:00","guid":{"rendered":"https:\/\/opentrons.com.cn\/?p=796"},"modified":"2024-04-18T16:52:32","modified_gmt":"2024-04-18T08:52:32","slug":"ot-2-press-release","status":"publish","type":"post","link":"https:\/\/en.opentrons.com.cn\/news\/ot-2-press-release\/","title":{"rendered":"OT-2 Press Release"},"content":{"rendered":"\n

New York City--March 27, 2018<\/strong>--Opentrons, a company providing laboratory automation services, today announced the launch of its newest laboratory robot, OT-2, and a new no-code protocol designer . The launch of OT-2 is supported by the closing of a $10 million seed funding round led by Khosla Ventures, with participation from Lerer Hippoau Ventures, Y Combinator Continuity Fund and former Pfizer CEO Jeff Kindler. This launch and funding furthers Opentrons\u2019 mission to bring affordable automation to any biologist.<\/p>\n\n\n\n

Biologists are poised to solve some of the world's biggest problems, but up to 90% of them still perform experiments manually because cost and complexity prevent them from automating them. Opentrons believes that laboratory automation should be affordable, customizable, and easy to use. Starting with its lab robots, the company automates hundreds of applications with the speed and accuracy of tools 10 times the price, aiming to free biologists from the tedious and error-prone manual pipetting process to speed scientific discovery. and progress.<\/p>\n\n\n\n

\"Life science investments are surging as the industry's potential for innovation, from drug development to biomanufacturing, is both exciting and inevitable,\" said Vinod Khosla, partner at Khosla Ventures. \"With automation, these developments can reduce costs and accelerate development.\" \"Opentrons not only brings affordable equipment to labs of all sizes, but also leverages the power of open source technology to foster a more collaborative scientific community. Now, lean biotech startups are possible.\"<\/p>\n\n\n\n

Since its inception, Opentrons' customer base and headcount have doubled every six months, and today hundreds of scientists and institutions use Opentrons, including 70% of the top ten pharmaceutical companies and 90% of the top 50 biological research universities. Fundraising supported the development of the OT-2 robot and will be used to maintain customers and the company's growth rate.<\/p>\n\n\n\n

About OT-2<\/h2>\n\n\n\n

Opentrons' newest robot, the OT-2, is small enough to fit on a bench and affordable for any size laboratory, allowing biologists to conduct experiments with the click of a button. OT-2 includes access to a library of validated protocols developed by hundreds of scientists from across the scientific community. Building on the design and success of Opentrons' first robot, OT One, OT-2 requires less technical expertise to use. Biologists can start with out-of-the-box preprogrammed protocols and adapt them to meet specific needs, or build their own protocols from scratch. The main functions of OT-2 include:<\/p>\n\n\n\n